Sign up for our daily briefing
Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.
Stay on top of the latest market trends
Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.
Sports news worthy of your time
Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.
Tech news worthy of your time
Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.
Get the inside stories
Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Want a daily digest of the top Denver news?
Get a daily digest of the most important stories affecting your hometown with Axios Denver
Want a daily digest of the top Des Moines news?
Get a daily digest of the most important stories affecting your hometown with Axios Des Moines
Want a daily digest of the top Twin Cities news?
Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities
Want a daily digest of the top Tampa Bay news?
Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay
Want a daily digest of the top Charlotte news?
Get a daily digest of the most important stories affecting your hometown with Axios Charlotte
Novum Pharma has gone to K Street. Photo: Bill Clark / CQ Roll Call via Getty Images
Novum Pharma, a small drug company that makes specialty skin creams, has hired its first lobbyists in Washington, D.C. — three lawyers at Buchanan Ingersoll & Rooney — who will advocate for undefined "pricing issues affecting the pharmaceutical industry."
Driving the news: Novum's federal lobbying document was signed just two days before Bloomberg published a profile of the company's top two leaders, who have been known to raise drug prices significantly. Michael Strazzela, one of Novum's lobbyists, said the registration had nothing to do with the Bloomberg story, and the company is interested in ways to "fix the broken pricing system."